Safety and Efficacy of Laparoscopic Truncal Vagotomy for the Treatment of Obesity
NCT ID: NCT00285220
Last Updated: 2009-02-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2005-09-30
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Endoscopic Sleeve Gastroplasty for Treatment of Obesity
NCT02231970
Assessment of Gastric Volume Reduction in Surgical Weight Loss Candidates
NCT00721227
Surgical Intervention in Bariatric Patients: Excess Weight Loss in the Morbidly Obese Following Gastric Plication
NCT01077193
Endoscopic Gastric Reduction for Weight Management
NCT01682733
Gastric Plication and Banding
NCT02072395
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Thereafter they will undergo a laparoscopic truncal vagotomy. Over 18 months, post operative tests of adequate vagotomy, weight loss, change in body composition and metabolism will be studied.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Laparoscopic Truncal Vagotomy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI 35-40 with comorbidity and BMI 40-45 with or without comorbidity
* Stable weight for the last 3 months
* willing to use contraceptives
* motivated to lose weight
* a personal history of at least one professionally supervised 6 month attempt or more than 2 serious attempts to loose weight
* fully ambulatory
Exclusion Criteria
* history of or signs and /or symptoms of gastro-duodenal ulcer disease
* abnormal vagus nerve testing
* current use of a list of medication
25 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
EndoVx, Inc.
INDUSTRY
University of California, San Francisco
OTHER
University of Rochester
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Lustig, MD
Role: PRINCIPAL_INVESTIGATOR
University of California, San Francisco
Marco Pattti, MD
Role: PRINCIPAL_INVESTIGATOR
University of California, San Francisco
Thad Boss, MD
Role: PRINCIPAL_INVESTIGATOR
University of Rochester
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California at San Francisco, Dept of Pediatrics
San Francisco, California, United States
Strong Health Bariatric Center at Highland Hospital
Rochester, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
00011552
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.